Yu Sunakawa

Sort by:

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given…

K. Fujita, Wataru Yamamoto, +15 authors Yasutsuna Sasaki
Cancer science
2008

S-1 is an oral anticancer agent composed of tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. CDHP is added to prevent degradation of 5-fluorouracil (5-FU) by inhibiting… (More)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Yu Sunakawa, Junji Furuse, +7 authors Yasutsuna Sasaki
Investigational New Drugs
2013

The safety, pharmacokinetics, and antitumor activity of the multikinase inhibitor regorafenib in Japanese patients was assessed in this multicenter, single-arm, phase I trial. Fifteen patients with… (More)

Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans

K. Fujita, Tomoko Sugiura, +9 authors Yukio Kato
Pharmaceutical Research
2013

Clinical study has previously revealed that plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, was higher in patients with end-stage renal failure… (More)

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

K. Fujita, Yuichi Ando, +16 authors Yasutsuna Sasaki
Cancer Chemotherapy and Pharmacology
2009

To investigate the effects of genetic polymorphisms on morphine-induced adverse events in cancer patients. We examined the relation of morphine-related adverse events to polymorphisms in… (More)

Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.

Yu Sunakawa, Heinz-Josef Lenz
Current treatment options in oncology
2015

Gastric cancer is a heterogenous cancer, which may be classified into several distinct subtypes based on pathology and epidemiology, each with different initiating pathological processes and each… (More)

Delayed elimination of SN-38 in cancer patients with severe renal failure.

K. Fujita, Yu Sunakawa, +15 authors Yasutsuna Sasaki
Drug metabolism and disposition: the biological…
2011

This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38),… (More)

Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus…

K. Fujita, Fumio Nagashima, +15 authors Yasutsuna Sasaki
Biological & pharmaceutical bulletin
2008

ATP-binding cassette, sub-family C, number 2 (ABCC2) is involved in the biliary excretion of irinotecan and its metabolites, SN-38 and SN-38 glucuronide. Effects of the ABCC2 genotype on the… (More)

Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.

Takashi Hirose, K. Fujita, +9 authors Yasutsuna Sasaki
Oncology reports
2010

We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK… (More)

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Yan Ning, Armin Gerger, +11 authors H. Lenz
Molecular cancer therapeutics
2014

Tumor recurrence after curative resection remains a major problem in patients with locally advanced colorectal cancer treated with adjuvant chemotherapy. Genetic single-nucleotide polymorphisms (SNP)… (More)

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.

Yu Sunakawa, Takeru Wakatsuki, +15 authors Heinz-Josef Lenz
Pharmacogenetics and genomics
2014

OBJECTIVE Dysregulation of the c-MET signaling pathway results from various molecular mechanisms including mutation, amplification, and overexpression. Overexpression and amplification of c-MET have… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences